JP2008514223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514223A5 JP2008514223A5 JP2007534174A JP2007534174A JP2008514223A5 JP 2008514223 A5 JP2008514223 A5 JP 2008514223A5 JP 2007534174 A JP2007534174 A JP 2007534174A JP 2007534174 A JP2007534174 A JP 2007534174A JP 2008514223 A5 JP2008514223 A5 JP 2008514223A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- present
- compound
- strand
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000000692 anti-sense Effects 0.000 claims 7
- 229920000972 Sense strand Polymers 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229920001914 Ribonucleotide Polymers 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002336 ribonucleotide Substances 0.000 claims 5
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 206010038436 Renal failure acute Diseases 0.000 claims 3
- 201000004384 alopecia Diseases 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 231100000895 deafness Toxicity 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 2
- 229920002676 Complementary DNA Polymers 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 229920001985 Small interfering RNA Polymers 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000002222 downregulating Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
Claims (21)
- 以下の構造を有するsiRNA化合物:
5' ugaagggugaaauauucuc-Z-3'(アンチセンス鎖 配列願号:48)
3'Z'-acuucccacuuuauaagag (センス鎖 配列願号:25);
ここで、a、c、u、およびgの各々はリボヌクレオチドであり、かつ各連続したリボヌクレオチドは共有結合によってリボヌクレオチドに連結されている;および
ここで、ZおよびZ'の各々は存在していても欠失していてもよいが、存在する場合はdTdTであり、それが存在する鎖の3’末端と共有結合する;および
ここで、アンチセンス鎖およびセンス鎖の両方における代替リボヌクレオチドは、その糖残基において修飾され、ここでは、2’-O-Me基が存在し、および、糖残基がアンチセンス鎖の5'および3'末端に存在し、および、糖残基がセンス鎖の5'および3'末端に存在する。 - 前記共有結合が、ホスホジエステル結合である、請求項1に記載の化合物。
- 前記ZおよびZ’が、ともに欠失している、請求項1または2に記載の化合物。
- 前記アンチセンスおよびセンス鎖が、3'および5’末端でリン酸化されていない、請求項1〜3のいずれか1項に記載の化合物。
- 前記アンチセンスおよびセンス鎖が、3'および5'末端でリン酸化されている、請求項1〜3のいずれか1項に記載の化合物。
- ヒトp53の発現を阻害するのに有効量の請求項1〜5のいずれか1項に記載の化合物と、キャリアとを含む薬学的組成物。
- 障害をもつ患者を治療するための薬剤の調製のための、請求項1〜5のいずれか1項に記載の化合物の使用。
- 前記患者が、主要な外科手術後に急性腎不全を発症するリスクが大きい、請求項7に記載の使用。
- 主要な外科手術後の患者における急性腎不全を防ぐための薬剤の調製のための、請求項7に記載の化合物の使用。
- 前記外科手術が、心臓外科手術である、請求項8または9に記載の使用。
- 前記障害が、シスプラチンによって誘発された聴覚消失症である、請求項7に記載の使用。
- 前記薬剤が、局所的投与用に調製される、請求項11に記載の使用。
- 前記障害が脱毛症である、請求項7に記載の使用。
- 遺伝子p53のmRNA転写物を以下の構造を有する化合物と接触させることを含む、対照と比較して少なくとも50%まで遺伝子p53の発現を下方制御する方法:
5' (N) x −Z 3’(アンチセンス鎖)
3' Z'−(N') y 5’(センス鎖)
各NおよびN’は、その糖残基において修飾されていても修飾されていなくてもよいリボヌクレオチドであり、かつ(N) x および(N') y は、各々連続的なNまたはN’が次のNまたはN’と共有結合によって連結しているオリゴマーであり;
xおよびyの各々は19〜40の整数であり;
ZおよびZ’の各々は存在していても欠失していてもよいが、存在する場合はdTdTであり、それが存在する鎖の3’末端と共有結合し;かつ
(N) x の配列は、表AからCに示されたp53のcDNAに対するアンチセンス配列を含む。 - p53ポリペプチドの上昇したレベルによってもたらされる疾患または障害を治療または予防するための薬剤の調製のための、ヒトp53を阻害するのに有効なsiRNA化合物の使用。
- 主要な外科手術後の患者の急性腎不全を防ぐための、請求項15に記載の使用。
- 前記外科手術が、心臓外科手術である、請求項16に記載の使用。
- シスプラチンによって誘発された聴覚消失症を治療するための、請求項15に記載の使用。
- 前記薬剤が、局所的投与用に調製される、請求項18に記載の使用。
- 前記障害が脱毛症である、請求項15に記載の使用。
- 前記脱毛症が、化学療法によって誘発される、請求項20に記載の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61399104P | 2004-09-28 | 2004-09-28 | |
US60/613,991 | 2004-09-28 | ||
US65819605P | 2005-03-02 | 2005-03-02 | |
US60/658,196 | 2005-03-02 | ||
US70302005P | 2005-07-26 | 2005-07-26 | |
US60/703,020 | 2005-07-26 | ||
PCT/IL2005/001035 WO2006035434A2 (en) | 2004-09-28 | 2005-09-27 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012049015A Division JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008514223A JP2008514223A (ja) | 2008-05-08 |
JP2008514223A5 true JP2008514223A5 (ja) | 2008-10-30 |
JP4991547B2 JP4991547B2 (ja) | 2012-08-01 |
Family
ID=36119277
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007534174A Expired - Fee Related JP4991547B2 (ja) | 2004-09-28 | 2005-09-27 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
JP2012049015A Withdrawn JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
JP2014147235A Expired - Fee Related JP5952350B2 (ja) | 2004-09-28 | 2014-07-17 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012049015A Withdrawn JP2012152216A (ja) | 2004-09-28 | 2012-03-06 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
JP2014147235A Expired - Fee Related JP5952350B2 (ja) | 2004-09-28 | 2014-07-17 | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
Country Status (19)
Country | Link |
---|---|
US (5) | US8765699B2 (ja) |
EP (1) | EP1799269B1 (ja) |
JP (3) | JP4991547B2 (ja) |
KR (2) | KR101357016B1 (ja) |
CN (1) | CN102643818B (ja) |
AU (1) | AU2005288522B2 (ja) |
BR (1) | BRPI0516177B8 (ja) |
CA (1) | CA2580126C (ja) |
DK (1) | DK1799269T3 (ja) |
ES (1) | ES2594083T3 (ja) |
HU (1) | HUE030844T2 (ja) |
LT (1) | LT1799269T (ja) |
MX (2) | MX2007003795A (ja) |
NZ (1) | NZ553987A (ja) |
PL (1) | PL1799269T3 (ja) |
PT (1) | PT1799269T (ja) |
RU (1) | RU2584609C2 (ja) |
SG (1) | SG161307A1 (ja) |
WO (1) | WO2006035434A2 (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040219569A1 (en) * | 1999-07-06 | 2004-11-04 | Fruma Yehiely | Gene identification method |
AU2001264317A1 (en) * | 2000-06-20 | 2002-01-02 | Koken Co., Ltd. | Preparations for oligonucleotide transfer |
CN1313158C (zh) * | 2001-06-20 | 2007-05-02 | 大日本住友制药株式会社 | 促进核酸转移的方法 |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
WO2005099772A2 (en) * | 2004-04-13 | 2005-10-27 | Boston Biomedical Research Institute | Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death |
US8361976B2 (en) * | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
US7741299B2 (en) | 2004-08-16 | 2010-06-22 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
BRPI0516177B8 (pt) | 2004-09-28 | 2021-05-25 | Quark Biotech Inc | oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 |
JP4131271B2 (ja) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | 情報処理装置および方法、並びにプログラム |
US20070135368A1 (en) * | 2005-12-09 | 2007-06-14 | Knapp Pamela E | Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
DOP2007000015A (es) * | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
AU2007302803A1 (en) * | 2006-10-02 | 2008-04-10 | Aprea Ab | RNA interference against Wrap53 to treat hyperproliferative diseases |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
DE102007008596B4 (de) * | 2007-02-15 | 2010-09-02 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung |
US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
WO2008126085A2 (en) * | 2007-04-12 | 2008-10-23 | Quark Pharmaceuticals, Inc. | Method for treating bone marrow disorders |
JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス, インコーポレイテッド | 遺伝子発現と疼痛 |
ES2474176T3 (es) * | 2007-06-27 | 2014-07-08 | Quark Pharmaceuticals, Inc. | Composiciones y métodos para inhibir la expresión de genes pro-apopt�ticos |
RU2487716C2 (ru) * | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
WO2009074990A2 (en) * | 2007-12-12 | 2009-06-18 | Quark Pharmaceuticals, Inc. | Rtp801l sirna compounds and methods of use thereof |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
US8431692B2 (en) * | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
JP2012517815A (ja) * | 2009-02-18 | 2012-08-09 | サイレンス・セラピューティクス・アーゲー | Ang2の発現を阻害するための手段 |
CN102458418B (zh) * | 2009-06-08 | 2015-09-16 | 夸克制药公司 | 一种寡核苷酸化合物的制药用途 |
EP3151005A1 (en) * | 2009-08-28 | 2017-04-05 | Astute Medical, Inc. | Methods for diagnosis of renal injury and renal failure |
US20130079382A1 (en) * | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
EP2649181B1 (en) * | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
CA2871089A1 (en) | 2011-04-20 | 2012-10-26 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
CN103145845A (zh) * | 2011-12-06 | 2013-06-12 | 吉林圣元科技有限责任公司 | Tat与人野生型P53融合蛋白在毕赤酵母中的表达 |
NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
WO2013170086A2 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
HUE054226T2 (hu) * | 2014-05-29 | 2021-08-30 | Quark Pharmaceuticals Inc | Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben |
ES2750689T3 (es) | 2014-08-15 | 2020-03-26 | Adynxx Inc | Señuelos oligonucleotídicos para el tratamiento del dolor |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
US20220025374A1 (en) * | 2018-01-12 | 2022-01-27 | University Of Massachusetts | Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2463774A1 (fr) * | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
CA2028756A1 (en) | 1989-11-24 | 1991-05-25 | Alfons H. M. Raeymaekers | Immunostimulating 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole derivatives |
US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ,インコーポレイテッド | 改変ヌクレオシド間結合 |
US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
GB9608937D0 (en) * | 1996-04-29 | 1996-07-03 | Cancer Res Campaign Tech | Screening methods for therapeutics and peptides used in the screen |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US5849774A (en) * | 1996-07-03 | 1998-12-15 | University Of Pittsburgh | Treatment of sepsis-induced acute renal failure |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO1999055910A1 (en) | 1998-04-24 | 1999-11-04 | Arizona Board Of Regents | Method of inducing apoptosis in a target cell |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
AU2156600A (en) * | 1998-11-25 | 2000-06-13 | Cold Spring Harbor Laboratory | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
CA2360671A1 (en) | 1999-01-29 | 2000-08-03 | The Board Of Trustees Of The University Of Illinois | P53 inhibitors and therapeutic use of the same |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
WO2001068336A2 (en) | 2000-03-16 | 2001-09-20 | Generis Gmbh | METHOD OF MANUFACTURING A STRUCTURAL PART BY MEANS OF A DEPOSIT TECHNIQUE |
KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US20020160393A1 (en) | 2000-12-28 | 2002-10-31 | Symonds Geoffrey P. | Double-stranded RNA-mediated gene suppression |
US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20040209832A1 (en) * | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
EP1470148B1 (en) | 2002-02-01 | 2012-07-18 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
EP1527176B2 (en) * | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
CN1780603A (zh) * | 2002-08-27 | 2006-05-31 | 雀巢制品公司 | 预防或治疗上皮组织损伤或毛发脱落 |
EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7781575B2 (en) * | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
PL1633767T3 (pl) | 2003-06-02 | 2019-07-31 | University Of Massachusetts | Sposoby i kompozycje do kontrolowania wydajności wyciszania rna |
WO2005062937A2 (en) | 2003-12-22 | 2005-07-14 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna |
CA2565701A1 (en) * | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
WO2005121372A2 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US7428919B2 (en) * | 2004-08-02 | 2008-09-30 | Young David P | Method and system for evaluating fluid flow through a heat exchanger |
US7741299B2 (en) * | 2004-08-16 | 2010-06-22 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
BRPI0516177B8 (pt) | 2004-09-28 | 2021-05-25 | Quark Biotech Inc | oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
ES2474176T3 (es) | 2007-06-27 | 2014-07-08 | Quark Pharmaceuticals, Inc. | Composiciones y métodos para inhibir la expresión de genes pro-apopt�ticos |
-
2005
- 2005-09-27 BR BRPI0516177A patent/BRPI0516177B8/pt not_active IP Right Cessation
- 2005-09-27 US US11/237,598 patent/US8765699B2/en active Active
- 2005-09-27 AU AU2005288522A patent/AU2005288522B2/en not_active Ceased
- 2005-09-27 WO PCT/IL2005/001035 patent/WO2006035434A2/en active Application Filing
- 2005-09-27 CA CA2580126A patent/CA2580126C/en not_active Expired - Fee Related
- 2005-09-27 CN CN201210097746.XA patent/CN102643818B/zh not_active Expired - Fee Related
- 2005-09-27 NZ NZ553987A patent/NZ553987A/en not_active IP Right Cessation
- 2005-09-27 SG SG201002811-6A patent/SG161307A1/en unknown
- 2005-09-27 JP JP2007534174A patent/JP4991547B2/ja not_active Expired - Fee Related
- 2005-09-27 LT LTEP05788492.6T patent/LT1799269T/lt unknown
- 2005-09-27 RU RU2011130434/10A patent/RU2584609C2/ru active
- 2005-09-27 PT PT57884926T patent/PT1799269T/pt unknown
- 2005-09-27 KR KR1020077009173A patent/KR101357016B1/ko active IP Right Grant
- 2005-09-27 HU HUE05788492A patent/HUE030844T2/en unknown
- 2005-09-27 ES ES05788492.6T patent/ES2594083T3/es active Active
- 2005-09-27 MX MX2007003795A patent/MX2007003795A/es active IP Right Grant
- 2005-09-27 KR KR1020127033760A patent/KR101409241B1/ko active IP Right Grant
- 2005-09-27 EP EP05788492.6A patent/EP1799269B1/en active Active
- 2005-09-27 DK DK05788492.6T patent/DK1799269T3/en active
- 2005-09-27 PL PL05788492T patent/PL1799269T3/pl unknown
-
2007
- 2007-03-28 MX MX2012001488A patent/MX336710B/es unknown
- 2007-07-10 US US11/827,199 patent/US7842674B2/en active Active
-
2008
- 2008-01-11 US US12/008,578 patent/US8148342B2/en not_active Expired - Fee Related
-
2012
- 2012-01-17 US US13/351,923 patent/US9006196B2/en not_active Expired - Fee Related
- 2012-03-06 JP JP2012049015A patent/JP2012152216A/ja not_active Withdrawn
-
2014
- 2014-07-01 US US14/321,484 patent/US9334499B2/en not_active Expired - Fee Related
- 2014-07-17 JP JP2014147235A patent/JP5952350B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008514223A5 (ja) | ||
JP5355856B2 (ja) | Vegfアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用 | |
AU2014244083B2 (en) | Methods for modulating chemotherapeutic cytotoxicity | |
EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
TWI702045B (zh) | 治療甲狀腺素運載蛋白(ttr)調節之澱粉樣變性的方法 | |
Veien et al. | Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study | |
RU2011130434A (ru) | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний | |
JP2008510019A5 (ja) | ||
Smith et al. | Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime | |
JP2020055884A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
JP2005512976A5 (ja) | ||
US20210389335A1 (en) | Compositions and methods for detection of smn protein in a subject and treatment of a subject | |
JP2015523855A (ja) | Apoa1及びabca1発現を調節するための組成物及び方法 | |
US20180282728A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
WO2010107508A1 (en) | Inhibiting gsnor | |
US20190071670A1 (en) | Methods Of Treatment For Alpha-1 Antitrypsin Deficiency | |
JP2016523548A5 (ja) | ||
EP2656850B1 (en) | Oligonucleotides for the treatment or alleviation of edema | |
Minor et al. | Prolonged methylene blue infusion in refractory septic shock: a case report | |
TW201919655A (zh) | 治療肌肉萎縮症的方法 | |
WO2016205631A1 (en) | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders | |
WO2010008474A4 (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
AU2018314236A1 (en) | RNA aptamers against transferrin receptor (TfR) | |
JP2022543136A (ja) | Apoc3関連疾患および障害の処置のための方法 |